Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Joint Bone Spine 89 (2022) 105283

Contents lists available at ScienceDirect

Joint Bone Spine

journal homepage: www.elsevier.com

Correspondence

Answer to Mungmunpuntipantip et al. "SARS CoV-2 vaccine AND rituximab" Joint Bone Spine 2021;88:105281

ARTICLE INFO

Keywords:
Rituximab
COVID
Vaccine

We thank Professor Mungmunpuntipantip for his comment [1]. We agree that immunization against SARS CoV2 is achieved through both humoral and cellular immunity. Concerning humoral immunity, several data are available showing, as in our case, a decrease in the humoral response to vaccination [2,3]. This element was expected. Recent studies suggested that specific T cell response after SARS-CoV-2 vaccination was still present in series of 11 and 46 patients treated with rituximab [4,5]. However, scientific knowledge is quickly evolving and a very recent study, conducted on 96 patients, found an alteration in post-vaccination cellular immunity [6] in patients treated with rituximab. Interestingly, the time since the last infusion was a prognostic factor for humoral and cellular vaccine response. The impact of rituximab on the vaccine response to SARS CoV2 is unclear and our case shows that infection after vaccination can occur. In view of this, great caution should be taken in our patients.

Funding support

None.

Disclosure of interest

The authors declare that they have no competing interest.

References

[1] Mungmunpuntipantip R, Wiwanitkit V. SARS CoV-2 vaccine AND rituximab. Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response" by Verhoeven et al. Joint Bone Spine 2021;88:105281.

[2] Cattaneo C, Cancelli V, Imberti L, et al. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. Blood Cancer J 2021;11:151.

[3] Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis 2021;80:1357–9.

[4] Prendecki M, Clarke C, Edwards H, et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis 2021;80:1322–9.

[5] Asplund Högelin K, Ruffin N, Pin E, et al. Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis. iScience 2021;24:103078.

[6] Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol 2021;10, http://dx.doi.org/10.1016/S2665-9913(21)00251-4.

Frank Verhoeven [a,b,*]
Quentin Lepiller [c]
Sophie Hecquet [a]
Clément Prati [a,b]
Daniel Wendling [a,d]

[a] *Department of Rheumatology, CHRU de Besançon, 3, boulevard Fleming, 25000 Besançon, France*
[b] *EA 4267 "PEPITE", UFR Santé, Franche-Comté University, 19, rue Ambroise Paré, bâtiment S, 25030 Besançon cedex, France*
[c] *Virology laboratory, CHRU de Besançon, 3, boulevard Fleming, 25000 Besançon, France*
[d] *EA 4266 « EPILAB », UFR Santé, Franche-Comté University, 19, rue Ambroise Paré, bâtiment S, 25030 Besançon cedex, France*

[*] Corresponding author at: Department of Rheumatology, CHRU Jean Minjoz, 3, boulevard Fleming, 25030 Besançon, France.
E-mail address: fverhoeven@chu-besancon.fr (F. Verhoeven)

Accepted 21 September 2021
Available online 1 October 2021

https://doi.org/10.1016/j.jbspin.2021.105283